Pasithea Therapeutics (KTTA)

• Market cap: $19.8M
• 1 day: -5.32%
• 5 days: -7.51%
• 1 month: 3.83%
• 3 months: 8.95%
• 6 months: 8.78%
• Year to date: -33.17%
• 1 year: -17.16%
• 5 years: -98.88%
• 10 years: -98.88%
• Sector: Healthcare
• Industry: Biotechnology

About: Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

Employees: 5